Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200355 | 0.91 | TRPV3 (0.46) | ALDH1A1TRPV3PSEN1PSEN2APH1B | |
| SCHEMBL2659430 | 0.90 | HDAC1 (0.41) | RARBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2271938 | 0.85 | RAB9A (0.43) | RAB9AKDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2275196 | 0.85 | RAB9A (0.43) | RAB9AKDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2275192 | 0.85 | RAB9A (0.43) | RAB9AKDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2274458 | 0.83 | KIF11 (0.42) | SMN1; SMN2MEN1KMT2ATLR8PSEN1 | |
| SCHEMBL2277014 | 0.83 | KIF11 (0.42) | SMN1; SMN2MEN1KMT2ATLR8PSEN1 | |
| SCHEMBL2267312 | 0.83 | KIF11 (0.42) | SMN1; SMN2MEN1KMT2ATLR8PSEN1 | |
| SCHEMBL2274456 | 0.83 | KIF11 (0.42) | SMN1; SMN2MEN1KMT2ATLR8PSEN1 | |
| SCHEMBL2274452 | 0.83 | KIF11 (0.42) | SMN1; SMN2MEN1KMT2ATLR8PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | RARB 2015/4885RAB9A 1889/4885KDM4E 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.